This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Current Discounted Rates End In:

  • 00
  • 00
  • 00
  • 00
Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Charles Allerson, Ph.D.
Vice President of Chemistry & Drug Development at DTx Pharma


Charles “Chuck” Allerson is the Vice President of Chemistry and Drug Development at DTx Pharma, where he oversees platform technology chemistry and early stage discovery efforts.  Prior to joining DTx Pharma, Chuck served as Vice President of Chemistry at Stoke Therapeutics, supporting the preclinical development of STK-001 for the treatment of Dravet Syndrome.  He has also held positions of Associate Director and Director of Chemistry at Regulus Therapeutics, where he led both medicinal and development chemistry efforts, and as Senior Scientist and Principal Scientist at Isis (Ionis) Pharmaceuticals.  Chuck received his Ph.D. in Chemistry from Harvard University, and did his postdoctoral studies at the NIH.

Agenda Sessions

  • Improved Delivery of RNA Therapeutics in the Eye, Muscle, and Beyond Using Fatty-Acid Conjugation